Table 3.
Adverse events (≥20% incidence) regardless of study drug relationship by preferred term (safety set) − overall (dose-escalation phase+follow-up phase)
Preferred term | All patients, n (%) |
Diarrhoea | 5 (50) |
Nausea | 5 (50) |
Fatigue | 3 (30) |
Hyperglycaemia | 3 (30) |
Hypophosphatemia | 3 (30) |
Chills | 2 (20) |
Tumour pain | 2 (20) |
Weight decreased | 2 (20) |